<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947813</url>
  </required_header>
  <id_info>
    <org_study_id>XHEC-C-2020-102-1</org_study_id>
    <nct_id>NCT04947813</nct_id>
  </id_info>
  <brief_title>Genotype-Phenotype Correlations in Patients With Alport Syndrome</brief_title>
  <official_title>Association Analysis Between Variants of COL4A3/COL4A4/COL4A5 and Alport Syndrome in the Han Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alport syndrome (AS) is caused by pathogenic variants in the type IV collagen genes COL4A3,&#xD;
      COL4A4, and COL4A5. This study aims to enroll families and patients with a history of renal&#xD;
      hematuria in 27 hospitals and detect these three genes for AS screening. This study also aims&#xD;
      to analysis the effect of COL4A3/COL4A4/COL4A5 genotype on the development of kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alport syndrome (AS) is a genetically and phenotypically heterogeneous disorder caused by the&#xD;
      mutations in the type IV collagen genes COL4A3, COL4A4, and COL4A5. In this study, next&#xD;
      generation sequencing is used to screen AS on 8165 participants enrolled from families and&#xD;
      patients with a history of renal hematuria in 27 hospitals of China Huadong Region. Genotype&#xD;
      (variants in COL4A3/COL4A4/COL4A5)-phenotype (onset age of hearing loss, nephroticrange&#xD;
      proteinuria, decline of eGFR, kidney survival and onset age of CKD5) correlations in AS were&#xD;
      evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification COL4A3/COL4A4/COL4A5 variants of Alport Syndrome</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>To characterize the variants of COL4A3/COL4A4/COL4A5 in patients with Alport syndrome over the course of up to 240 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification genotype-phenotype correlations of Alport Syndrome</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>Exploring correlations between variants of COL4A3/COL4A4/COL4A5 and the clinical robustness including onset age of hearing loss, nephroticrange proteinuria, decline of eGFR, kidney survival and onset age of CKD5 in Alport syndrome patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">8165</enrollment>
  <condition>Alport Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other&#xD;
        26 hospitals of China Huadong Region.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: up to 99 Years (Child, Adult, Older Adult)&#xD;
&#xD;
          2. Sex: All;&#xD;
&#xD;
          3. Families and patients with a history of renal hematuria;&#xD;
&#xD;
          4. Those who signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Polycystic kidney disease, hypertensive nephropathy, etc.;&#xD;
&#xD;
          2. Kidney biopsy is diagnosed as other primary/secondary kidney disease without type IV&#xD;
             collagen-related kidney disease, including IgA nephropathy, membranous nephropathy,&#xD;
             lupus nephritis, etc.&#xD;
&#xD;
          3. Incomplete medical history or clinical data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gengru Jiang</last_name>
      <phone>+86-13917983703</phone>
      <email>jianggeng-ru@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

